The Cuprizone Model: Reading Demyelination and Remyelination Without the Autoimmune Noise
Remyelination has become the most interesting frontier in multiple sclerosis. The approved therapies for relapsing disease are effective at...
preclinical drug development (2)
BoNT in Postsurgical Pain: Mechanistic and Behavioral Findings from a Porcine SMIR Model
Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications for several decades. Its...
Adult Tissue and Sex Diversity in SCI: Translational Drug Development
Spinal cord injury presents one of the most challenging translational profiles in central nervous system drug development. The clinical need is...
GLP Toxicology Studies in Neuroscience
Toxicology is a defining step between exploratory research and clinical development. As programs move toward IND-enabling requirements, the need for...
Critical Endpoints in Preclinical Pain Studies: Behavioral, Biomarker, and Electrophysiology Assessments
Developing effective therapeutics for pain requires selecting endpoints that accurately reflect the biological, functional, and neurophysiological...
MD Biosciences Signs the Marseille Declaration
MD Biosciences has signed the Marseille Declaration, the first joint pharmaceutical industry statement on animal housing and use. By signing, we...
How Close Are We to Clinical Translation? Large-Animal Models for SCI
Spinal cord injury (SCI) remains one of the most challenging neurological conditions to treat, with few therapies successfully translating from the...
Approaches to Designing Preclinical Studies That Reflect Clinical Reality
Bridging the gap between preclinical and clinical research remains one of the most pressing challenges in drug development. While early-stage studies...
EWMA 2025: Groundbreaking AI-Driven Advancements in Wound Healing Models
MD Biosciences presented at the European Wound Management Association 2025 in Barcelona. Dr. Avital Schauder showcased groundbreaking research on...